Global Foundation for the Care of Newborn Infants (GFCNI)
München, Bavaria, 81379, Germany
Location status: Recruiting
NCT Number: NCT07134387
The objective of this study is to examine the long-term impact of having a child with Bronchopulmonary Dysplasia (BPD) on the parents and caregivers from the time of diagnosis through adulthood. The primary focus will be on parents and caregivers of children until the age of 18 (< 18) years who were diagnosed with BPD as newborns. Data will be collected through an online questionnaire in France, Germany, Italy, the Netherlands, Spain, the United Kingdom (including Northern Ireland), and the United States. It will ask about inclusion and exclusion criteria, background information (caregiver, child, and family situation), the child's medical situation, parental health-related quality of life (HRQoL), health literacy, feelings, support structures, and economic burden of the family.
Interested in participating?
Request Info0 year–18 year
All sexes
Observational
München, Bavaria, 81379, Germany
Location status: Recruiting
The study will be designed as an observational, cross-sectional survey with a comparison group using a self-administered, web-based questionnaire for retrospective data collection. The study will use a multi-lingual online survey collecting data from parents in France, Germany, Italy, the Netherlands, Spain, the United Kingdom (including Northern Ireland), and the United States. Following a participatory research approach, the study will be carried out in close collaboration with representatives of national and international parent organizations, affected parents and/or former patients, professional healthcare societies, healthcare professionals as well as health researchers in the form of a Project Expert Group (PEG). It includes medical experts in BPD and neonatal/pediatric care, parent representatives, and, if applicable, parents of children affected by BPD during the neonatal period and/or affected patients from the countries of interest. The PEG will be complemented by the External Scientific Advisory Board (ESAB), which comprises n=4 members, including researchers specializing in HRQoL and/or pediatric respiratory outcomes research, including BPD. The PEG and ESAB will be engaged in all stages of the research project through regular online meetings. The ESAB contributes mainly to the study design and conception, questionnaire development, data analysis and interpretation, and will support the development of scientific publications. The remaining members of the PEG are involved in reviewing all final materials generated from the project and support the recruitment of study participants, as well as the dissemination of findings within their professional networks.
After comprehensive literature research and exchange with the study experts, the questionnaire will be drafted considering the already existing PedsQL Family Impact Module (FIM) (15) to assess parental HRQoL. In addition to socio-demographic information and inclusion/exclusion criteria, the questionnaire includes items evaluating various dimensions of parental HRQoL, health literacy and support structures. Furthermore, questions assessing the child's medical situation, treatment and eventual co-morbidities during the newborn period as well as at the time of the current survey will be added. Ultimately, questions addressing the financial burden of medical costs will be considered to assess the personal impact as well as the impact on the healthcare system in the respective countries. A unified questionnaire will be utilized for all participants, irrespective of their group assignment. Participants will be assigned to the BPD or comparison group retrospectively, based on their answers defining the BPD-status. To enhance comprehension, the questionnaire avoids using the term "BPD" wherever feasible and instead employs a more general reference to lung problems.
The questionnaire draft will be developed in close collaboration with the ESAB and reviewed by the PEG. After implementing necessary changes, the updated version will be shared again with the expert groups for final review. In addition, a pretest with up to 10 participants resembling the target group will be performed to elaborate on understanding, relevance and completeness as well as to elucidate other relevant topics that have not yet been covered and still need to be included.
After a potential adaptation based on data and information of the pre-testing, the questionnaire will be translated in the respective country languages with the PEG reviewing the translations. The translated questionnaire versions will be transferred into the online survey software SurveyMonkey® and will be distributed via the PEG/ESAB, GFCNI's network, GFCNI's newsletter and social media channels via an access link.
GFCNI received a research grant from Chiesi in support of this independent study.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
BPD-group:
Control group:
Exclusion criteria
BPD-group:
Control group:
A unified questionnaire will be utilized for all participants, irrespective of their group assignment. Participants will be assigned to the BPD or comparison group retrospectively, based on their answers defining the BPD-status. To enhance comprehension, the questionnaire avoids using the term "BPD" wherever feasible and instead employs a more general reference to lung problems.
Time frame: 09/2025 - 02/2026
To record the parents' HRQoL, the Pediatric Quality of Life Inventory Family Impact Module (PedsQL FIM) is implemented, a validated and widely used instrument designed to measure the impact of pediatric acute and chronic health conditions on parents and the family. It consists of 36 items across six parental dimensions (physical, emotional, social, and cognitive functioning, communication, and worry), as well as family daily activities and relationships. It is validated in all official languages of the seven participating countries (English, French, German, Italian, Dutch, Spanish) and allows the calculation of a sum score.
Time frame: 09/2025 - 02/2026
Inclusion/exclusion criteria, Baseline characteristics, socio-demographic characteristics of parent/caregiver, child, and the family situation
Time frame: 09/2025 - 02/2026
The section assesses the child's overall health, daily functioning, school attendance, and involvement of medical specialists. It covers emotional, cognitive, and behavioral issues (potentially linked to BPD), respiratory health (symptoms, infections, treatments, support), and feeding difficulties. It also records comorbidities and developmental impairments, and includes questions on RSV prevention and infection history.
Time frame: 09/2025 - 02/2026
The Family Finances section captures family costs related to caring for a child with health conditions, including direct and broader economic impacts such as financial burden, work productivity loss, and healthcare utilization.
Time frame: 09/2025 - 02/2026
Disease awareness and awareness of consequences
Time frame: 09/2025 - 02/2026
Contact information is provided by the study sponsor or research team.
Christina Tischer, Dr
CONTACT
+49 (0)89 / 89083260
Julia Feiler, Dr
CONTACT
Global Foundation for the Care of Newborn Infants
Other
BronQ Family: Assessing the Long-term Impact of Bronchopulmonary Dysplasia (BPD) on Affected Families' Health-related Quality of Life
Acronym: BronQ Family
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07101640
Bronchopulmonary Dysplasia, Bronchopulmonary Dysplasia (BPD)
Little Rock, Arkansas, United States
View Trial DetailsNCT07652684
Bronchopulmonary Dysplasia, Bronchopulmonary Dysplasia (BPD)
Thessaloniki, Greece
View Trial DetailsNCT07120971
Bronchopulmonary Dysplasia, Bronchopulmonary Dysplasia (BPD)
Milwaukee, Wisconsin, United States
View Trial DetailsNCT07109791
Antibiotic-Resistant Organisms (AROs), Bronchopulmonary Dysplasia
Edmonton, Alberta, Canada
View Trial Details